This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Brightseed Co-Founder Sofia Elizondo breaks down what plant bioactives are, and how they're using the latest technology to study human's biological connections with plants.
On this episode of Cheddar Innovates: Brightseed Co-Founder breaks down what plant bioactives are, and how they're using the latest technology to study human's biological connections with plants; Esper Bionics CEO breaks down how they re creating a mind-controlled bionic hand that guest smarter the more you use it; Cheddar gets a look at Curiosity Stream's 'Capturing A Black Hole In Our Milky Way.'
Hilary Kearney, Founder of Girl Next Door Honey, joined Closing Bell to discuss her partnership with Comvita to save the important pollinators, as bee colonies are on the decline across the United States.
Hurricane climatologist Jill Trepanier joined Cheddar News to discuss NOAA's announced prediction for an above-normal hurricane season and what it might mean for people in the United States. "I think it's important that people who maybe haven't been used to having extreme weather events related to say tropical cycles and tropical systems, like thinking New Jersey, Northeastern seaboard, that area may get more action than they're used to in the past," she said.
Dr. Jarrad Aguirre, Co-Founder and CEO of Miga Health, joins Cheddar News' Closing Bell, where he says his company is looking to establish the future of heart health and points to how 80% of premature heart attacks and strokes are preventable.
On this episode of Cheddar Reveals, David Keith, Professor of Applied Physics at the Harvard School of Engineering and Applied Sciences and Professor of Public Policy at the Harvard Kennedy School, and founder of Carbon Engineering outlines the viability of solar geoengineering as a solution to help reverse the effects of global warming; Lena Geraghty, Sustainability & Urban Innovation Director at National League of Cities, discusses which U.S. cities are safest from global warming and how the real estate market will be impacted from the effects of climate change; Cheddar gets a look at Curiosity Stream's 'Changing Ocean Asia.'
David Keith, Professor of Applied Physics at the Harvard School of Engineering and Applied Sciences and Professor of Public Policy at the Harvard Kennedy School, and founder of Carbon Engineering joins Cheddar Reveals to outline the viability of solar geoengineering as a solution to help reverse the effects of global warming.
Lena Geraghty, Sustainability & Urban Innovation Director at National League of Cities, joins Cheddar News to discuss which U.S. cities are safest from global warming and how the real estate market will be impacted from the effects of climate change.
Peggy Whitson, Director of Human Space Flight, Axiom Space, joins Cheddar Innovates to discuss Axiom's involvement in the first fully-private mission to the ISS, and her experience spending 665 days in space.
On this episode of Cheddar Innovates, Peggy Whitson, Director of Human Space Flight, Axiom Space, breaks down Axiom's involvement in the first fully-private mission to the ISS, and her experience spending 665 days in space; William Li and Danielle Chang, co-founders of The Hao Life, discuss how they're shaking up the $71 billion supplement industry by putting a modern spin on traditional natural Chinese remedies; Cheddar gets a look at Curiosity Stream's 'Sagrada Familia: Gaudi's Challenge.'
